Aclaris Therapeutics To Present Results From Open-Label Phase 2a Trial Of ATI-2138, Investigational Oral Covalent Inhibitor Of Interleukin-2-ITK And JAK3, At 2026 AAD Annual Meeting

Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announced that it will present results from its open-label Phase 2a trial of ATI-2138, an investigational oral covalent inhibitor targeting ITK and JAK3, at the 2026 AAD Annual Meeting in Denver, CO. The presentation will include previously unreported results from the trial involving patients with moderate-to-severe atopic dermatitis.